GHRH and cancer: The proliferation of T47Ds, MDA-MB-468, MDA-MB-435, LNCaP and NCI H838 cancer cell line was also inhibited by 31–37%, 26–31%, 31–38%, 34–41%, 37–42% respectively after exposure to GHRH antagonist JMR-132 at doses of 0.1 and 1 μM.